Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 29-May-20 4:51 PM View:  | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 367,333 | -- | -- | (9%) 4.3M to 3.93M | |
| 29-May-20 4:51 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 412,236 | -- | -- | (9%) 4.67M to 4.26M | |
| 29-May-20 4:51 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 44,903 | -- | -- | (1%) 3.93M to 3.88M | |
| 13-Dec-19 2:08 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-19 | Market Sale | 1,200,000 | $105.47 | $126,564,000.00 | (22%) 5.38M to 4.18M | 2% |
| 13-Dec-19 2:18 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-19 | Market Sale Duplicate | 1,200,000 | $105.47 | $126,564,000.00 | (22%) 5.38M to 4.18M | 2% |
| 26-Feb-20 5:41 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 21-Nov-18 | Market Sale | 20,000 | $112.54 | $2,250,800.00 | (100%) 20.0K to 0 | 8% |
| 23-Nov-18 8:53 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 20-Nov-18 | Market Purchase | 4,000 | $117.88 | $471,520.00 | 3% 157.13K to 161.13K | 15% |
| 26-Feb-20 6:06 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Sale | 10,000 | $131.60 | $1,316,000.00 | (33%) 30.0K to 20.0K | 21% |
| 19-Nov-18 6:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Purchase | 4,000 | $124.00 | $496,000.00 | 3% 153.13K to 157.13K | 9% |
| 19-Nov-18 6:09 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Purchase | 2,000 | $124.69 | $249,387.00 | < 1% 296.07K to 298.07K | 8% |
| 14-Nov-18 6:43 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Nov-18 | Option Exercise | 10,000 | $16.46 | $164,600.00 | 50% 20.0K to 30.0K | |
| 19-Sep-18 4:25 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 18-Sep-18 | Option Exercise | 20,000 | $9.45 | $189,000.00 | 100% 0 to 20.0K | |
| 12-Jun-18 9:02 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 5,908 | $287.46 | $1,698,310.00 | < 1% 5.65M to 5.65M | (53%) |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Option Exercise | 7,957 | $86.64 | $689,409.00 | 18% 43.81K to 51.77K | |
| 12-Jun-18 8:56 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale Duplicate | 73,526 | $287.46 | $21,135,800.00 | (10%) 729.07K to 655.54K | 53% |
| 12-Jun-18 9:02 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 274,092 | $287.46 | $78,790,496.00 | (5%) 5.65M to 5.38M | 53% |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Option Sale | 7,957 | $287.46 | $2,287,320.00 | (15%) 51.77K to 43.81K | 53% |
| 12-Jun-18 8:55 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 73,526 | $287.46 | $21,135,800.00 | 13% 582.01K to 655.54K | (53%) |
| 12-Jun-18 8:50 PM View: | Bay City Capital LLC Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 280,000 | $287.46 | $80,488,800.00 | (5%) 5.66M to 5.38M | 53% |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 2,142 | $287.46 | $615,739.00 | (5%) 43.81K to 41.67K | 53% |
| 24-Aug-17 4:04 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Aug-17 | Market Purchase | 2,000 | $16.12 | $32,235.90 | 28% 7.1K to 9.1K | 739% |
| 23-Aug-17 4:03 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Aug-17 | Market Purchase | 3,550 | $16.12 | $57,209.10 | 100% 3.55K to 7.1K | 740% |
| 22-Aug-17 4:05 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 21-Aug-17 | Market Purchase | 3,550 | $15.88 | $56,358.30 | 100% 0 to 3.55K | 752% |
| 26-Jul-16 5:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant Duplicate | 729,066 | -- | -- | 507% 143.7K to 872.77K | |
| 22-Jul-16 5:22 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 25,714 | -- | -- | 1200% 2.14K to 27.86K | |
| 22-Jul-16 5:23 PM View: | Schor Chen Former President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 42,857 | -- | -- | 500% 8.57K to 51.43K | |
| 26-Jul-16 5:25 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 432,872 | -- | -- | 59% 729.07K to 1.16M | |
| 26-Jul-16 5:55 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 296,067 | -- | -- | 100% 0 to 296.07K | |
| 26-Jul-16 5:26 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 22,969 | -- | -- | 119% 19.31K to 42.28K | |
| 22-Jul-16 5:18 PM View: | Rieder Wendy E Former SVP, Gen. Counsel | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 25,714 | -- | -- | 4543% 0.57K to 26.28K | |
| 22-Jul-16 5:23 PM View: | Schor Chen Former President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 14,250 | $9.48 | $135,090.00 | (28%) 51.43K to 37.18K | |
| 26-Jul-16 5:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 143,703 | -- | -- | 100% 0 to 143.7K | |
| 26-Jul-16 5:55 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 5,657,850 | -- | -- | 1911% 296.07K to 5.95M | |
| 22-Jul-16 5:22 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 8,548 | $9.48 | $81,035.00 | (31%) 27.86K to 19.31K | |
| 22-Jul-16 5:18 PM View: | Rieder Wendy E Former SVP, Gen. Counsel | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 8,550 | $9.48 | $81,054.00 | (33%) 26.28K to 17.73K | |
| 26-Jul-16 5:25 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 729,066 | -- | -- | 100% 0 to 729.07K | |
| 05-Jan-16 6:32 PM View: | Morenstein Scott D Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Jan-16 | Grant | 17,857 | -- | -- | 100% 0 to 17.86K | |
| 15-Dec-15 4:34 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-15 | Market Sale | 300,000 | $0.32 | $96,690.00 | (12%) 2.42M to 2.12M | (1087%) |
| 15-Dec-15 4:34 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Dec-15 | Market Sale | 300,000 | $0.37 | $111,030.00 | (11%) 2.72M to 2.42M | (934%) |
| 09-Dec-15 5:00 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 09-Dec-15 | Market Sale | 145,892 | $0.38 | $55,234.70 | (5%) 2.86M to 2.72M | (911%) |
| 08-Dec-15 2:09 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 08-Dec-15 | Market Sale | 1,369,640 | $0.37 | $506,766.00 | (6%) 23.08M to 21.71M | (934%) |
| 09-Dec-15 5:00 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 08-Dec-15 | Market Sale | 300,000 | $0.38 | $114,060.00 | (9%) 3.16M to 2.86M | (906%) |
| 09-Dec-15 5:00 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 07-Dec-15 | Market Sale | 300,000 | $0.39 | $115,830.00 | (9%) 3.46M to 3.16M | (891%) |
| 08-Dec-15 2:09 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 07-Dec-15 | Market Sale | 100 | $0.41 | $41.00 | (< 1%) 23.08M to 23.08M | (833%) |
| 08-Dec-15 2:09 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 04-Dec-15 | Market Sale | 153,607 | $0.41 | $63,347.50 | (< 1%) 23.24M to 23.08M | (828%) |
| 03-Dec-15 5:49 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 03-Dec-15 | Market Sale | 262,434 | $0.41 | $108,621.00 | (1%) 23.5M to 23.24M | (825%) |
| 03-Dec-15 5:49 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 02-Dec-15 | Market Sale | 687,603 | $0.43 | $293,744.00 | (3%) 24.19M to 23.5M | (796%) |
| 03-Dec-15 5:49 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 01-Dec-15 | Market Sale | 480,716 | $0.43 | $206,804.00 | (2%) 24.67M to 24.19M | (789%) |
| 30-Nov-15 5:23 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 30-Nov-15 | Market Sale | 640,505 | $0.43 | $277,659.00 | (3%) 25.31M to 24.67M | (783%) |
| 30-Nov-15 5:23 PM View: | Kovner Bruce Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-Nov-15 | Market Sale | 934,595 | $0.50 | $462,625.00 | (4%) 26.24M to 25.31M | (673%) |
